This list is an analysis based on recent market events. It's not an investment recommendation.
About
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
The current price of 8Z1.F is €15.5 EUR — it has increased by +0% in the past 24 hours. Watch PharmaEssentia stock price performance more closely on the chart.
What is PharmaEssentia stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PharmaEssentia stocks are traded under the ticker 8Z1.F.
When is the next PharmaEssentia earnings date?▼
PharmaEssentia is going to release the next earnings report on May 08, 2026.
What were PharmaEssentia earnings last quarter?▼
8Z1.F earnings for the last quarter are 0.11 EUR per share, whereas the estimation was 0.1 EUR resulting in a +10.07% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is PharmaEssentia revenue for the last year?▼
PharmaEssentia revenue for the last year amounts to 861.65M EUR.
What is PharmaEssentia net income for the last year?▼
8Z1.F net income for the last year is 277.74M EUR.
Does PharmaEssentia pay dividends?▼
Yes, 8Z1.F dividends are paid annual. The last dividend per share was 0.03 EUR. As of today, Dividend Yield (FWD)% is 0.21%.
When did PharmaEssentia complete a stock split?▼
PharmaEssentia has not had any recent stock splits.